Society of Gynecologic Oncology Annual Meeting on Women's Cancer (SGO 2022)

Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?

Roshini Claire Anthony, 20220505180001

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer

Audrey Abella, 20220429100000

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

Intraperitoneal carboplatin ups PFS in ovarian cancer

Should intraperitoneal chemo be reconsidered for ovarian cancer?

Pearl Toh, 20220428150100

Progression-free survival (PFS) is significantly longer with intraperitoneal (IP) over intravenous (IV) carboplatin, when combined with dose-dense paclitaxel, in patients with ovarian, fallopian tube, or primary peritoneal cancer, regardless of residual tumour size after initial surgery, according to the phase III iPocc* trial presented at SGO 2022.

Tislelizumab a potential treatment alternative for gynaecologic MSI-H/dMMR tumours

Audrey Abella, 20220420100000

The humanized IgG4 monoclonal antibody tislelizumab was clinically active in women with gynaecologic microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) solid tumours, and was generally well-tolerated with no new safety signals, according to a subgroup analysis of the phase II RATIONALE 209 study presented at SGO 2022.

Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer

Roshini Claire Anthony, 20220414180001

Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.

First-line niraparib maintenance regimen boosts PFS in advanced ovarian cancer

Roshini Claire Anthony, 20220411160001

First-line maintenance therapy with niraparib at an individualized starting dose (ISD) improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer, according to results of the phase III PRIME study presented at SGO 2022.

MIRV shows promise in FRα-high, platinum-resistant ovarian cancer

MIRV shows promise in platinum-resistant ovarian cancer

Pearl Toh, 20220409160100

The first-in-class antibody-drug conjugate mirvetuximab soravtansine (MIRV) shows promising anti-tumour activity in previously treated patients with platinum-resistant ovarian cancer who express high levels of folate receptor alpha (FRα), according to the SORAYA study presented at SGO 2022.